期刊文献+

我院缺血性卒中一、二级预防抗栓药物应用状况 被引量:2

The cross-sectional study on the status of antithrombotic in primary and secondary prevention of ischemic stroke inpatients in neurology department
原文传递
导出
摘要 目的:了解缺血性卒中住院患者一、二级预防抗栓药物的应用现状,为该类患者二级预防合理使用抗栓药物提供参考。方法:研究对象为急性脑梗死住院患者,对其出院带药(方案)进行用药指导,同时调查其入院之前卒中一、二级预防抗栓药物的应用状况。结果:入选患者共178例,其中第1次发作106例,使用抗栓药物者36例(一级预防抗栓药物使用率34%),第2次及以上发作72例,使用抗血栓药物者56例(二级预防78%);在92例使用抗栓药物进行卒中一、二级预防的患者中,以规范的剂量和频次服用阿司匹林和氯吡格雷者56例(61%);长期服药者46例(坚持服药率50%)。结论:缺血性卒中患者一、二级预防抗栓药物的应用现状不容乐观,存在其应用比例较少、剂量不足、服药间断现象。临床医生、药师应对缺血性卒中患者一、二级预防抗栓药物的合理使用应给予正确、全面指导,以提高用药的依从性。 OBJECTIVE To investigate the status of the application of antithrombotic in primary and secondary prevention of ischemic stroke and to provide reference for improving the secondary prevention. METHODS The study was a cross sectional investigation. All inpatients in diagnosis of acute cerebral infarction were guided for discharge medication and we inw.stigated the application of antithrombotic before admission. RESULTS 178 patients were involved, the cases of first stroke attack were 106, among them 36 patients applied antithrombotic, the cases of second and above stroke altack were 72, among them 56, patients applied antithrombotic. 56 cases were administrated aspirin and clopidogrel in slandard dose and frequeney of 92 patients. The cases of continous use of antithrombotic were 46 (compliance rate is 50%). CONCLUSION The status of the application of antithrombotic in primary and secondary prevention on acute ischemic stroke was not optimistic, there was a small proportion and low dose and discontinuance of application of antithrombotic. Doctors and pharmacists should pay attention to the compliance of antithrombotic in primary and secondary prevention of ischemic stroke.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2010年第22期1930-1933,共4页 Chinese Journal of Hospital Pharmacy
关键词 缺血性卒中 、二级预防 抗栓药物 ischemic stroke primary and secondary prevention antithrombotic
  • 相关文献

参考文献4

二级参考文献18

  • 1吴敌,马锐华,王伊龙,王拥军.缺血性卒中二级预防的药物依从性调查[J].中华内科杂志,2005,44(7):506-508. 被引量:38
  • 2Antithrombotic Trialists′ Collaboration.Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death,myocardial infarction,and stroke in high risk patients.BMJ,2002,324:71-86. 被引量:1
  • 3Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events.The SALT Collaborative Group.Lancet,1991,338:1345-1349. 被引量:1
  • 4European Stroke Prevention Study 2.Efficacy and safety data.J Neurol Sci,1997,151 Suppl:S1-S77. 被引量:1
  • 5Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke.EAFT (European Atrial Fibrillation Trial) Study Group.Lancet,1993,342:1255-1262. 被引量:1
  • 6Ridker PM,Cook NR,Lee IM,et al.A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.N Engl J Med,2005,352:1293-1304. 被引量:1
  • 7The International Stroke Trial (IST):a randomised trial of aspirin,subcutaneous heparin,both,or neither among 19435 patients with acute ischaemic stroke.International Stroke Trial Collaborative Group.Lancet,1997,349:1569-1581. 被引量:1
  • 8CAST:randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke.CAST (Chinese Acute Stroke Trial) Collaborative Group.Lancet,1997,349:1641-1649. 被引量:1
  • 9Sacco RL, Adams R, Albers G, et al; American Heart Association; American Stroke Association Council on Stroke; Council on Cardiovascular Radiology and Intervention; American Academy of Neurology.Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke, 2006, 37:577 -617. 被引量:1
  • 10Bhatt DL, Fox KA, Hacke W, et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med, 2006, 354:1706 - 1717. 被引量:1

共引文献33174

同被引文献48

  • 1高润霖,钱杰,Charles H Hennekens.预防心血管疾病:中国需要更广泛和正确地使用阿司匹林[J].中国实用内科杂志,2007,27(1):78-81. 被引量:25
  • 2Kuzniatsova N,Shantsila E, Blann A, et al. A contemporary view- point on "aspirin resistance" [J]. Ann Med, 2012,44(8) :773 - 783. 被引量:1
  • 3Fitzgerald R, Pirmohamed M. Aspirin resistance:effect of clinical, biochemical and genetic factors [ J ]. Pharmacol Ther, 2011,130 (2) :213 -225. 被引量:1
  • 4Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2 [ J ]. Annu Rev Pharmacol Toxicol,1998,38( 18 ) :97 -120. 被引量:1
  • 5Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cartdiovascular disease: a meta-analysis [ J ]. Am J Med, 2008,121 ( 1 ) :43 - 49. 被引量:1
  • 6Yansuf O, Bhatt DL. The evolution of antiplatelet therapy in cardio- vascular disease [ J ]. Nat Rev Cardio1,2011,8 ( 10 ) :547 - 559. 被引量:1
  • 7Baigent C, Blaekwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta- analysis of in dividual participant data from randomised trials[ J]. Lancet,2009,373 (9678) : 1849 - 1860. 被引量:1
  • 8Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle braehial index : a randomized controlled trial [ J ]. JAMA, 2010,303 (9) :841 - 848. 被引量:1
  • 9Berger JS, Lala A, Krantz M J, et al. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease:a meta-analysis of randomized trials [ J ]. Am Heart J,2011,162(1) :115 -124. 被引量:1
  • 10Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple primary prevention trials of eardiovascular events using aspirin [ J]. Am J Cardiol,2011,107(12) : 1796 - 1801. 被引量:1

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部